-
CorMedix NasdaqGM:CRMD CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Location: 300 Connell Drive, Berkeley Heights, NJ, 07922, United States | Website: https://www.cormedix.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
751.8M
Cash
77.5M
Avg Qtr Burn
-3.392M
Short % of Float
12.60%
Insider Ownership
1.19%
Institutional Own.
36.99%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DefenCath® (taurolidine and heparin) Details Infectious disease, Catheter related blood stream infections | Approved Quarterly sales | |
DefenCath® (taurolidine and heparin) Details Infectious disease, Catheter related blood stream infections, TPN patients | Phase 3 Initiation |